The API Patent Cliff 2026–2029: Which Molecules Have Suppliers Ready
Patent expiry lists are everywhere. What they almost never show is whether anyone actually holds a current filing for the ingredient. We took 92 active pharmaceutical ingredientswhose last listed US product patent expires within three years and counted the organisations holding an active US DMF or a valid EU CEP for each. 35 have fewer than three. 19 have none on record.
Edition of 23 October 2026 (first edition August 2026) · Sources: FDA Orange Book, FDA Drug Master Files, EDQM · Data and query
Reviewed by Dr Sanaz Baheran, PhD in pharmaceutical science, co-founder of PharmaTek
Key findings
Patent expiry is not the same as a generic opportunity
19 of the 92 molecules whose last listed product patent expires by 2029 have no organisation with a current US DMF or EU CEP on record, and a further 16 have only one or two. That does not mean no one makes them: supply may sit outside these registers. It does mean a buyer cannot find a documented source in public records, and qualifying one can take longer than the patent has left to run.
The crowded end is very crowded
At the other extreme, 24 molecules already have ten or more organisations with a current DMF or CEP, led by pregabalin with 42 across 197 Orange Book products. Where this many organisations hold current filings, finding a documented source is unlikely to be the hard part; the filings do not show who can supply at scale, on what terms, or how quickly.
A current filing is a starting point, not a qualified source
An active DMF or valid CEP shows a filing a buyer can reference. It says nothing about GMP status at the site making the substance, capacity or price, so each candidate still needs qualification. The API pages show each organisation's records and any GMP documents matched to its sites.
Current documented sources across the cliff
The 92 APIs expiring by 2029, grouped by how many organisations hold a current DMF or CEP. Average across the group: 6.6.
Red and amber together account for 35 of 92 molecules.
Most documented sources
The most organisations with a current DMF or CEP.
No current DMF or CEP on record
Approved products exist; no organisation holds a current US DMF or EU CEP in our data. Supply may exist outside these registers.
What this means for generics planning
The last listed product patent date is one input to launch timing, not the answer: products can carry several patents and exclusivities, some covering a formulation or use rather than the ingredient, and freedom to operate needs product-by-product legal review. It also says nothing about whether you can obtain the ingredient, and the two questions have very different lead times. Qualifying a new API supplier — audit, samples, stability, regulatory filing — routinely takes eighteen months to three years. For the 35 molecules on this list with fewer than three documented current sources, that clock is already running.
One way to read the list is in three groups. Where many organisations hold current filings, documented sources exist and the sourcing work is comparing and qualifying them. Where there are one or two, a buyer may need to qualify the only documented holder or develop another. Where none is on record, obtaining the ingredient may mean developing a source rather than buying from one. None of this measures commercial readiness, capacity or price: filing counts are a prompt for those questions, not an answer.
The count of documented sources is also a rough guide to switching risk after launch. A molecule with a single documented source may be a single point of failure regardless of how attractive the market looks, and it is worth weighing that against the DMF and GMP standing of whoever does make it.
Each substance page shows its product patent dates, current and historical DMF and CEP holders, and weekly changes to those records, so this analysis is a starting point rather than a one-off snapshot. Search any molecule in the supplier directory.
Reproduce this report
This edition counts organisations with an active DMF or a valid CEP. The August 2026 edition counted all suppliers on record, including inactive DMFs (90 ingredients; 16 with none). Data, query and limitations
Methodology & sources
- Patent and exclusivity dates come from the FDA Orange Book. We hold dated patent information for 683 substances; 92 have a latest-patent expiry between 23 October 2026 and 23 October 2029, and 156 within five years.
- “Current sources” counts distinct organisations with an active US Type II Drug Master File or a valid EU Certificate of Suitability for the substance, the rule the API pages use. It measures publicly evidenced supply: a manufacturer serving only non-US, non-EU markets, or supplying without a DMF, will not appear. Zero therefore means “none on public record”, not “none in existence”.
- Where approved products containing a substance carry several patents we use the latest listed expiry across those products. That date is product-level: it can relate to a formulation, combination or method of use, and an earlier generic of another product may already be possible. Exclusivity periods are tracked separately; this analysis is organised by the latest listed patent date and is not legal advice on market entry.
- This compares product-patent dates with documented sources (current DMFs and CEPs). It is not an assessment of commercial supply, capacity or readiness, and not legal advice: patent status varies by jurisdiction and by formulation, and freedom to operate should be confirmed with counsel.
Cite this report: PharmaTek Intelligence, “The API Patent Cliff 2026–2029: Which Molecules Have Suppliers Ready,” edition of 23 October 2026. https://pharmatek.co.uk/reports/api-patent-cliff
See who supplies any molecule on this list
Patent dates, API suppliers, GMP certificates and inspection history for thousands of substances — in one place.
Explore the directory